We noted you are experiencing viewing problems
- 
        
        Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
 - 
        
        Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. - 
        
        No luck yet? More tips for troubleshooting viewing issues
 - 
        
        Contact HST Support access@hstalks.com
 
- 
        Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
 - 
        For additional help, please don't hesitate to contact HST support access@hstalks.com
 
We hope you have enjoyed this limited-length demo
                    
                    This is a limited length demo talk; you may
                    
                      login or
                    
                    review methods of
                    obtaining more access.
                  
                
                
              Printable Handouts
Navigable Slide Index
- Introduction
 - Bioterrorism/biowarfare
 - CDC priority list of pathogens
 - Viruses as BW agents
 - Effective viral biothreats
 - Biodefense vaccines
 - Viral biothreats
 - Smallpox description
 - Smallpox historical BW threat
 - Smallpox eradication
 - Smallpox: the disease
 - Smallpox: pros as a biothreat
 - Smallpox: cons as a biothreat
 - CDC vaccination plan for a BT event
 - Monkeypox
 - Smallpox: live Vaccinia virus vaccines
 - Smallpox: MVA (modified Vaccinia virus Ankara)
 - Smallpox: vaccines - risk vs. benefit
 - Smallpox: therapeutics - cidofovir
 - Smallpox: therapeutics - ST-246
 - Smallpox - BW/BT considerations
 - Equine encephalitis viruses
 - VEEV, EEEV, WEEV
 - U.S. cases of EEE
 - U.S. cases of WEE
 - Natural EEEV and WEEV cycles
 - Natural VEEV cycles
 - VEE outbreaks
 - Existing Alphavirus vaccines
 - Next generation vaccines
 - VEEV, EEEV, WEEV - BW/BT considerations
 - Viral hemorrhagic fevers
 - Virus families causing VHF
 - Viral hemorrhagic fever distribution
 - Symptoms of VHF
 - Treatment of VHF
 - Filoviruses
 - VHF as BW agents: Marburg and Ebola viruses
 - Filoviruse distribution
 - Filoviruse mortality
 - Ebola hemorrhagic fever
 - Marburg hemorrhagic fever
 - Ebola hemorrhagic fever - disease symptoms
 - Treatment of filovirus infections
 - Stopping a filovirus epidemic
 - Filovirus vaccine development
 - FHF - BW/BT considerations
 - Rift Valley fever virus
 - RVF historically exclusive in Africa
 - RVF in Saudi Arabia/Yemen 2002
 - Correlation of rainfall to outbreaks of RVFV
 - RVF ongoing outbreak - Kenya
 - RVF - human disease
 - Treatment of RVFV
 - RVF - animal disease
 - Rift valley fever vaccines (1)
 - Rift valley fever vaccines (2)
 - Rift valley fever vaccines (3)
 - Rift Valley fever virus - BW/BT considerations
 - Other challenges
 - Conclusions
 
Topics Covered
- Viruses as bioterrorism or biowarfare threats
 - Smallpox virus and monkeypox virus
 - Equine encephalitis viruses: Venezuelan, eastern and western equine encephalitis viruses
 - Ebola and Marburg viruses
 - Rift Valley fever virus
 - Genetically engineered viruses
 
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Schmaljohn, C. (2007, October 1). Biodefense challenges [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 4, 2025, from https://doi.org/10.69645/XERH2882.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Connie Schmaljohn has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.